Investigators analyzed the next-generation sequencing data of DNA and RNA from 14,287 colorectal cancer cases included in the data set of a commercial Clinical Laboratory Improvement Amendments-certified laboratory. The cases were divided into two groups based on the median value of CD47 gene expression levels.
[Journal For Immunotherapy of Cancer]
